2021

Hologic closes acquisition of Mobidiag

June 17, 2021
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.

“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”

Mobidiag to Be Acquired by Hologic, Innovator in Women’s Health Diagnostic Testing, for Approximately €668 Million

Transaction Will Accelerate Global Growth of Mobidiag’s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Capability and Rapid Turnaround Time —

ESPOO, Finland, April 08, 2021 — Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, for an enterprise value of approximately €668 million ($795 million).  This includes a cash payment of approximately €600 million ($714 million) for Mobidiag’s equity, and net debt of approximately €68 million ($81 million).

Combo respiratory tests Resp-4

Mobidiag receives CE-IVD for Amplidiag® RESP-4 for simultaneous detection of COVID-19, Flu A, Flu B and RSV

  • Real-time PCR-based test enables high-throughput reliable detection of most prevalent respiratory infections, including COVID-19
  • One single test determines the virus responsible for patient symptoms, guiding treatment decisions and rapid isolation strategy if required

FINLAND, Espoo, March 1st, 2021 – Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.

These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The See poster

Amplidiag® and Novodiag® solutions now available through distribution in Norway

Mobidiag Ltd. today announces that it has signed an agreement with XboXLab for the distribution of its molecular diagnostic products Amplidiag® and Novodiag® in Norway.

We are very pleased to expand our distribution network and be able to provide Norwegian clinical laboratories with our innovative molecular diagnostic solutions.

For more information, please contact :
Henning Jansen
+47 40 33 00 11
henning.jansen@xboxlab.no
www.xboxlab.se

Mobidiag products are also available throughout Europe and the Middle East. Visit our See poster

2020

Mobidiag Receives Second Tranche of €25M Financing from European Investment Bank

  • Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019
  • New funds will be used to accelerate the development, manufacturing and commercialisation of in vitro diagnostics for infectious diseases
  • Mobidiag offers complete diagnostic solution for the detection of novel coronavirus infections with both PCR and antibody tests

  • CE-IVD marked molecular diagnostic tests on the Novodiag and Amplidiag platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release
  • Antibody test for detection of past COVID-19 infections
  • Secure supply chain and in-house manufacturing capabilities to meet demand
  • Molecular diagnostics of coronavirus infection with Novodiag

    Novodiag® COVID-19, a fully automated molecular diagnostic test, granted emergency use authorization in Finland for novel coronavirus

  • Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;
  • provides safety for users with a closed system;
  • easy to use with no need for highly trained personnel enabling decentralized testing.
  • Molecular diagnostics of coronavirus infection with Amplidiag

    Amplidiag® COVID-19 molecular diagnostic test granted emergency use authorization in Finland for novel coronavirus

    – Real-time PCR-based test enables high-throughput reliable detection of early COVID-19 infections for rapid isolation and treatment guidance

    – Currently set up for routine use in main Finnish clinical labs with capacity to test up to 4,000 samples per day

    Mobidiag Ltd. announces that it has received emergency use authorization in Finland for its Amplidiag® COVID-19 molecular diagnostic test for the rapid detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Amplidiag® COVID-19 is now available for use in Finland*. The test will be run for routine use at the main clinical laboratories in Finland (Helsinki University Hospital (Huslab), SYNLAB and Mehiläinen) doubling Finnish testing capacity and allowing testing coverage for most of the country. The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France. Mobidiag w

    Development of Novodiag® assay for safe and easy molecular testing of novel coronavirus and influenza viruses

    Novodiag® assay rapidly detects coronavirus and influenzas;
    provides safety for users with a closed system;
    easy to use with no need for highly trained personnel in high risk and hard to reach areas

    Mobidiag Ltd. today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.

    The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.

    The new Novodiag® test will operate using a rapid ‘sample-in, result-out’ system, allowing the rapid detection of both novel coronavirus and influenzas in around 30 minutes. In addition, the fully automa

    Mobidiag Secures Additional Funding from Business Finland for Rapid Sepsis Diagnostic Test

    ESPOO, Finland, January 07, 2020 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has been granted EUR 1.5 million ($1.65 million) additional funding from Business Finland (formerly Tekes) for the continued development of a rapid diagnostic test for sepsis using Mobidiag’s Novodiag platform. This additional funding has been secured as a result of strong progress in the development of the assay and the completion of key milestones by Mobidiag since the award of the first grant in May 2018. The new funding brings the total loan to EUR 3 million ($3.3 million).

    Mobidiag is harnessing the power of its Novodiag platform to develop a fast, simple and reliable syndromic assay to detect sepsis within two hours, directly from a patient’s bl

    Page suivante »